Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.